{"organizations": [], "uuid": "a61dbc4b89c087f5e9ad30b0684fe0a1ab7c4704", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-seattle-genetics-and-pieris-pharma/brief-seattle-genetics-and-pieris-pharmaceuticals-announce-multi-program-immuno-oncology-collaboration-idUSFWN1PZ0XU", "country": "US", "domain_rank": 408, "title": "BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-09T13:50:00.000+02:00", "replies_count": 0, "uuid": "a61dbc4b89c087f5e9ad30b0684fe0a1ab7c4704"}, "author": "", "url": "https://www.reuters.com/article/brief-seattle-genetics-and-pieris-pharma/brief-seattle-genetics-and-pieris-pharmaceuticals-announce-multi-program-immuno-oncology-collaboration-idUSFWN1PZ0XU", "ord_in_thread": 0, "title": "BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration", "locations": [], "entities": {"persons": [], "locations": [{"name": "seattle", "sentiment": "none"}], "organizations": [{"name": "brief-seattle genetics and pieris pharmaceuticals", "sentiment": "negative"}, {"name": "seattle", "sentiment": "none"}, {"name": "pieris", "sentiment": "none"}, {"name": "immuno-oncology collaboration reuters", "sentiment": "none"}, {"name": "seattle genetics - co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "pieris pharmaceuticals inc", "sentiment": "none"}, {"name": "seattle genetics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 52 AM / Updated 8 minutes ago BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration Reuters Staff \nFeb 9 (Reuters) - Pieris Pharmaceuticals Inc: \n* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION \n* SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL PAY PIERIS A $30 MILLION UPFRONT FEE, TIERED ROYALTIES ON NET SALES UP TO LOW DOUBLE-DIGITS​ \n* SEATTLE GENETICS - CO, PIERIS TO EVALUATE BISPECIFIC IMMUNO-ONCOLOGY AGENTS COMBINING PIERIS’ ANTICALIN TECHNOLOGY WITH SOME OF CO‘S CANCER-TARGETED ANTIBODIES \n* SEATTLE GENETICS - UNDER TERMS OF AGREEMENT CO TO PAY PIERIS UP TO $1.2 BILLION IN TOTAL SUCCESS-BASED PAYMENTS ACROSS THREE PRODUCT CANDIDATES \n* SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL SOLELY DEVELOP, FUND AND COMMERCIALIZE OTHER TWO PROGRAMS​ \n* SEATTLE GENETICS-PIERIS PHARMA, CO HAVE ENTERED INTO AGREEMENT FOR DEVELOPING MULTIPLE TARGETED BISPECIFIC IMMUNO-ONCOLOGY TREATMENTS FOR BLOOD CANCERS \n* SEATTLE GENETICS INC - ‍PRIOR TO INITIATION OF A PIVOTAL TRIAL, PIERIS MAY OPT INTO GLOBAL CO-DEVELOPMENT AND U.S. COMMERCIALIZATION OF SECOND PROGRAM​ \n* SEATTLE GENETICS - PRIOR TO INITIATION OF PIVOTAL TRIAL, PIERIS MAY OPT FOR A SHARE IN GLOBAL COSTS, PROFITS ON 50/50 BASIS FOR SECOND PROGRAM Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-09T13:50:00.000+02:00", "crawled": "2018-02-09T14:04:26.009+02:00", "highlightTitle": ""}